Literature DB >> 11937555

Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.

Anne C Armstrong1, Said Dermime, Christopher G Allinson, Tapan Bhattacharyya, Kate Mulryan, Karin R Gonzalez, Peter L Stern, Robert E Hawkins.   

Abstract

The Ig Id of a B cell lymphoma is a tumor-specific Ag, although as a self-Ag it is likely to be a weak immunogen. Provision of a foreign gene may enhance the immunogenicity of the idiotype. Viral vectors allow highly efficient transfer of genetic material and are themselves innately immunogenic. We have investigated the ability of recombinant adenoviral vectors, encoding the idiotypic gene with or without fusion to the human Fc region, to produce anti-idiotypic Ab- and T cell-mediated responses in a syngeneic BALB/c A20 murine lymphoma model. The idiotypic V(H) and V(L) sequences were assembled as a single chain variable fragment (scFv) and adenoviral vectors encoding the A20 scFv (Ad.A20) and A20 scFv linked to the Fc fragment of human IgG1 (Ad.A20hFc) were constructed. A single immunization of BALB/c mice with Ad.A20hFc but not Ad.A20 induced a specific anti-idiotypic Ab response. T cell lines generated from mice vaccinated with either vector displayed specific cytotoxicity, proliferation, and IFN-gamma release against a syngeneic dendritic cell line transduced using a retroviral vector to express the A20 scFv idiotype (XS52.A1.A20). Importantly, both T cell lines lysed the A20 lymphoma cells. An immunodominant H-2K(d)-restricted CD8(+) T cell peptide, DYWGQGTEL (A20[106-114]), was identified as a naturally occurring A20 scFv epitope. A single immunization with Ad.A20hFc but not Ad.A20 provided protection in >40% of animals challenged with a lethal dose of the A20 tumor line and was more effective, in this model, than a previously optimized plasmid vaccine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11937555     DOI: 10.4049/jimmunol.168.8.3983

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses.

Authors:  Roberta Schiavo; Dolgor Baatar; Purevdorj Olkhanud; Fred E Indig; Nicholas Restifo; Dennis Taub; Arya Biragyn
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

2.  Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model.

Authors:  Eric A Weaver; Christopher Y Chen; Shannon M May; Mary E Barry; Michael A Barry
Journal:  Hum Gene Ther       Date:  2011-09-06       Impact factor: 5.695

3.  Therapeutic vaccines for aggressive B-cell lymphoma.

Authors:  Zijun Y Xu-Monette; Ken H Young
Journal:  Leuk Lymphoma       Date:  2020-08-25

4.  Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.

Authors:  Alejandro López-Requena; Oscar R Burrone; Michela Cesco-Gaspere
Journal:  Front Oncol       Date:  2012-11-09       Impact factor: 6.244

5.  Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells.

Authors:  Max Warncke; Maike Buchner; Gudrun Thaller; Anna Dodero; Alla Bulashevska; Dietmar Pfeifer; Jens Timmer; Hendrik Veelken
Journal:  Cancer Immunol Immunother       Date:  2010-09-17       Impact factor: 6.968

6.  Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

Authors:  D R Newell; K M Searle; N B Westwood; S S Burtles
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

7.  Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma.

Authors:  Erkuden Casales; Eva Martisova; Helena Villanueva; Ascensión López Díaz de Cerio; Susana Inoges; Noelia Silva-Pilipich; María Cristina Ballesteros-Briones; Alejandro Aranda; Jaione Bezunartea; Maurizio Bendandi; Fernando Pastor; Cristian Smerdou
Journal:  Sci Rep       Date:  2021-11-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.